IL218390A0 - Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs - Google Patents

Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs

Info

Publication number
IL218390A0
IL218390A0 IL218390A IL21839012A IL218390A0 IL 218390 A0 IL218390 A0 IL 218390A0 IL 218390 A IL218390 A IL 218390A IL 21839012 A IL21839012 A IL 21839012A IL 218390 A0 IL218390 A0 IL 218390A0
Authority
IL
Israel
Prior art keywords
thiohydantoins
sustituted
heteroarylmethyl
anticancer drugs
anticancer
Prior art date
Application number
IL218390A
Other languages
English (en)
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of IL218390A0 publication Critical patent/IL218390A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL218390A 2009-09-11 2012-02-29 Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs IL218390A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Publications (1)

Publication Number Publication Date
IL218390A0 true IL218390A0 (en) 2012-04-30

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218390A IL218390A0 (en) 2009-09-11 2012-02-29 Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs

Country Status (28)

Country Link
US (1) US20120251551A1 (OSRAM)
EP (1) EP2475653A1 (OSRAM)
JP (1) JP2013504523A (OSRAM)
KR (1) KR20120065396A (OSRAM)
CN (1) CN102639523A (OSRAM)
AR (1) AR078166A1 (OSRAM)
AU (1) AU2010294588A1 (OSRAM)
BR (1) BR112012005526A2 (OSRAM)
CA (1) CA2773591A1 (OSRAM)
CL (1) CL2012000623A1 (OSRAM)
CO (1) CO6511228A2 (OSRAM)
CR (1) CR20120113A (OSRAM)
CU (1) CU20120042A7 (OSRAM)
DO (1) DOP2012000063A (OSRAM)
EA (1) EA201200473A1 (OSRAM)
EC (1) ECSP12011716A (OSRAM)
IL (1) IL218390A0 (OSRAM)
IN (1) IN2012DN02081A (OSRAM)
MA (1) MA33566B1 (OSRAM)
MX (1) MX2012002977A (OSRAM)
NZ (1) NZ598643A (OSRAM)
PE (1) PE20121180A1 (OSRAM)
PH (1) PH12012500497A1 (OSRAM)
SG (1) SG178919A1 (OSRAM)
TN (1) TN2012000108A1 (OSRAM)
TW (1) TW201111378A (OSRAM)
UY (1) UY32882A (OSRAM)
WO (1) WO2011029537A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03410B (me) 2010-02-17 2020-01-20 Takeda Pharmaceuticals Co Heterociklična jedinjenja
EP2576536B1 (en) * 2010-06-01 2016-09-14 The University of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
HRP20182096T1 (hr) 2011-12-22 2019-02-22 Alios Biopharma, Inc. Supstituirani nukleozidi, nukleotidi i njihovi analozi
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
KR102532198B1 (ko) 2012-12-21 2023-05-11 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
FI3080100T3 (fi) * 2013-12-11 2023-03-15 Celgene Quanticel Res Inc Lysiinispesifisen demetylaasi-1:n estäjät
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
WO2015169677A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
WO2017060167A1 (en) 2015-10-08 2017-04-13 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CN110770210A (zh) 2017-05-18 2020-02-07 Pi工业有限公司 新颖的脒化合物
AU2019221019B2 (en) 2018-02-13 2024-05-02 Bayer Aktiengesellschaft Use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
AU2020271767B2 (en) 2019-04-11 2025-02-27 Stem Synergy Therapeutics, Inc Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
US20230135524A1 (en) * 2020-01-21 2023-05-04 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
WO2022206742A1 (zh) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
ATE384048T1 (de) 1998-09-22 2008-02-15 Astellas Pharma Inc Cyanophenyl-derivate
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CA2482382A1 (en) 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
AU2004256084B2 (en) 2003-07-02 2007-10-18 Kyorin Pharmaceutical Co., Ltd. Oxazolidinone antibiotics and derivatives thereof
TW200526637A (en) 2003-09-30 2005-08-16 Janssen Pharmaceutica Nv Benzoimidazole compounds
WO2005061463A1 (en) 2003-12-23 2005-07-07 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US7803826B2 (en) 2004-08-03 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Imidazolidine derivatives
CA2579886A1 (en) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
AU2005311534B2 (en) 2004-12-03 2011-02-17 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as H3 antagonists
KR102713358B1 (ko) * 2005-05-13 2024-10-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
TW201716385A (zh) 2007-10-26 2017-05-16 加州大學董事會 二芳基乙內醯脲類化合物
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
US20120251551A1 (en) 2012-10-04
WO2011029537A1 (en) 2011-03-17
EA201200473A1 (ru) 2012-10-30
CR20120113A (es) 2012-05-02
MA33566B1 (fr) 2012-09-01
CO6511228A2 (es) 2012-08-31
CA2773591A1 (en) 2011-03-17
TW201111378A (en) 2011-04-01
CN102639523A (zh) 2012-08-15
SG178919A1 (en) 2012-04-27
TN2012000108A1 (en) 2013-09-19
AU2010294588A1 (en) 2012-04-05
CU20120042A7 (es) 2012-06-21
MX2012002977A (es) 2012-04-30
UY32882A (es) 2011-04-29
PH12012500497A1 (en) 2012-10-22
CL2012000623A1 (es) 2012-09-14
JP2013504523A (ja) 2013-02-07
PE20121180A1 (es) 2012-08-24
AR078166A1 (es) 2011-10-19
IN2012DN02081A (OSRAM) 2015-08-21
EP2475653A1 (en) 2012-07-18
KR20120065396A (ko) 2012-06-20
NZ598643A (en) 2013-10-25
DOP2012000063A (es) 2012-05-15
BR112012005526A2 (pt) 2016-04-26
ECSP12011716A (es) 2012-04-30

Similar Documents

Publication Publication Date Title
IL218390A0 (en) Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs
GB2481835B8 (en) Shelving system
GB2472672B (en) Shelving system
PL2401027T3 (pl) Układ do interwencyjnego dostarczania leku
GB0903810D0 (en) Delivery system
EP2486315A4 (en) Horizontal connecting device
EP2489002A4 (en) VIRTUAL ADVERTISING FIGURE
GB2487287B (en) Atmospheric delivery system
EP2449521A4 (en) SELECTIVE EXTRACTION OF CONTENT
GB0815093D0 (en) Extraction system
ZA201200761B (en) Tablet
IL220026A0 (en) Card sharing prevention
AU330360S (en) Tablet
IL217206A0 (en) Receiving content
WO2012042540A9 (en) Anticancer agent
GB2475155B (en) Multi function monitor
GB0920041D0 (en) Tablet
AP2012006060A0 (en) Display device.
PL2134258T3 (pl) Układ nakłuwający
PL2226272T3 (pl) System regałowy
EP2596627A4 (en) OUTPUT OF CONTENT OF MULTIPLE EQUIPMENT
GB0811599D0 (en) Improvements in anticancer drugs
GB2486432B (en) Greeting cards
GB0920699D0 (en) Dihydroetorphine
AU2009902203A0 (en) False lumen device